Tata Consultancy Services whitepaper

The Clinical Trial Supplies Control Tower: Gain End to End Visibility for your Clinical Supplies

Clinical trials are getting more global, complex, larger and focused, with CROs facing added pressure to complete them faster. Dynamic market changes demonstrate a need for more collaborative IT solutions that can address new risks across the clinical trials supply chain. The control tower can be leveraged to make these clinical supply chains more responsive, beyond time zone, geography and …

Press Release: MyMeds&Me announce collaboration with Oracle Health Sciences

Oracle Argus Safety customers gain access to the Reportum® solution to further streamline and strengthen their Pharmacovigilance operations London, UK, 25 March, 2015: MyMeds&Me, a leading SaaS provider of web-based adverse event and product quality capture solutions for life sciences, today announced their collaboration with Oracle Health Sciences to provide the Reportum® solution to Oracle Argus safety customers. This collaboration …

Asia & its patient recruitment potential for clinical trials

In today’s whitepaper release, featured company ClinActis, shares their insight on patient recruitment strategies in Asia and the possible approaches for the different regions in APAC. ______________ According to the 2012 Tufts CSDD study, clinical site activation rates in Asia Pacific are at one of the highest, with 91% of sites successfully progressing through the study start up stages and …

Download White Paper : Engaging Clinical Trial Sites – The Role of the Clinical Trial Liaison

Enrollment in clinical trials is heavily dependent on two very important customers: the research subject and the clinical trial investigator. Research subjects are highly valuable since it is obviously impossible to complete a clinical trial without a willing group of participants. There are many groups and even entire companies that specialize in engaging potential subjects and connecting them to clinical …

Ebook: 10 reasons why clinical trials fail

It is a time of exciting change in the clinical trial sector as new technologies, innovative processes and levels of patient engagement open up new opportunities for clinical research. It’s so important that we really understand the changes that need to happen so we can embrace new technologies and operational changes that will provide valuable long term improvements. It is vital …

Download: A-Z of Clinical Trials

Clinical trials are currently undergoing a massive overhaul in how they are designed and executed. With the cost of clinical trials skyrocketing in the west, new innovations are providing researchers with the tools to improve data quality whilst reducing costs: Something that is especially important given drying up of the new substance pipelines across the pharmaceutical industry. In March 2014 …

Innovation in Pharma 2013: Top tips for the future

Last week saw Deloitte publish it’s fourth annual report looking at the return on investment pharmaceutical companies are seeing in their research and development projects. The report, co-produced with Thomson Reuters, looks at the current state of development pipelines in 12 top life science companies, and calculates a projected financial return for their products in the late stages of the …

Costly Protocols Unnecessary? How much you gain by cutting them out of your clinical development

Medidata and Tufts University School of Medicine have recently concluded in their report that unnecessary procedures in clinical trials costs the industry up to $5bn a year. Does this call for changes in the way protocols are formulated? But which self-respecting individual would risk undermining his team's years of efforts in the different phases of clinical trials by carrying out …